Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
No Placebo
Drugs
Locations
Clinical Specialty
2121-2140 of 2,251 trials

PCOS Fertility: Letrozole vs. Gonadotropins

We are studying whether continuing ovulation induction with letrozole is more effective than switching to gonadotropins for women with polycystic ovary syndrome. The trial also looks at safety, quality of life, and costs related to fertility treatment.

Polycystic Ovary Syndrome (PCOS)1-2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesPartially RemoteEndocrinologyGynecology and ObstetricsInternal Medicine

Personalized Treatment for High-Risk Breast Cancer: PETREMAC Trial

We are studying how personalized therapies can improve outcomes for patients with high-risk breast cancer. The trial looks at treatment responses and aims to enhance surgical options while ensuring safety.

Breast Cancer>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesOncology

Glioblastoma: Adding Zoledronic Acid to Treatment

We are studying whether adding zoledronic acid to standard chemotherapy can help improve survival and treatment response in patients with glioblastoma. We also want to assess its safety and tolerability.

Glioblastoma3-6 monthsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesPartially RemoteNeurologyOncology

Bowel Dysfunction After Rectal Cancer Surgery: Irrigation vs. Suppositories

We are comparing transanal irrigation and glycerol suppositories to see which treatment better improves bowel function and quality of life for patients after rectal cancer surgery.

Low Anterior Resection Syndrome≤3 monthsConfirmation phase (III)Monitoring phase (IV)No PlaceboStandard MedicinesPartially RemoteGastroenterologyInternal Medicine

Blood Cancer Treatment: CCS1477 Study

We are testing the safety and effects of the experimental drug CCS1477 in patients with advanced blood and bone marrow cancers. This study aims to see how well it works alone and in combination with other treatments.

Acute Myeloid Leukaemia (AML)Myelodysplastic Syndrome (MDS)Multiple Myeloma (MM)Safety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesHematologyOncology

Lung Transplantation: Heparin-Free Heart-Lung Support

We are studying a new method of heart-lung support without blood thinners during lung transplantation. This trial aims to see if it is safe and effective for improving patient outcomes.

Lung Transplantation1-2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesInternal MedicinePulmonology

Prostate Cancer: Androgen Deprivation Therapy and PSMA

We are studying how androgen deprivation therapy affects the expression of a specific protein in metastatic prostate cancer. This research may help us understand treatment responses and disease progression better.

Metastatic Prostate Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncologyUrology

Autoimmune Disease: CAR-Expressing NK Cell Therapy

We are testing a new therapy using engineered immune cells for people with active B-cell driven autoimmune diseases. The study aims to assess safety and effectiveness in conditions like lupus and scleroderma.

Systemic Lupus ErythematosusSystemic SclerosisIdiopathic Inflammatory MyopathySafety phase (I)Efficacy phase (II)16-20 visitsNo PlaceboInvestigational MedicinesInfectious DiseasesRheumatology

Vaginal Estrogen Treatment: Effects on Blood Clotting

We are studying how local vaginal estrogen affects blood clotting in postmenopausal women. This includes examining its impact on women with a history of blood clots.

Vulvovaginal Atrophy>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesGynecology and ObstetricsInternal Medicine

Meningococcal Vaccine Study for Ages 10-20

We are testing a booster dose of the rMenB+OMV NZ vaccine in healthy participants aged 10 to 20 who were vaccinated in early childhood. The study aims to see how well it enhances their immune response and evaluates its safety.

Invasive Meningococcal DiseaseConfirmation phase (III)≤5 visitsNo PlaceboInvestigational MedicinesInfectious DiseasesPediatrics

Solid Tumors: MK-5684 Study

We are testing a new treatment, MK-5684, for people with certain solid tumors to see if it helps them live longer without disease progression. The study also evaluates its safety and effectiveness compared to standard care.

Breast CancerOvarian CancerEndometrial Cancer6-12 monthsEfficacy phase (II)Confirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesOncology

Chronic Heart Failure: Combined Diuretic Therapy Study

We are comparing a new combined diuretic treatment to standard therapies for people with chronic heart failure. The goal is to see if it improves exercise capacity and fluid management.

Congestive Heart Failure>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesCardiologyInternal Medicine

Rezafungin for Chronic Pulmonary Aspergillosis Treatment

We are studying whether rezafungin can effectively treat chronic pulmonary aspergillosis in adults with few treatment options. The trial will assess both the effectiveness and safety of this medication.

Chronic Pulmonary Aspergillosis6-12 monthsEfficacy phase (II)>20 visitsNo PlaceboStandard MedicinesCost ReimbursementInfectious DiseasesPulmonology

Melanoma Treatment: Comparing Immune Therapies

We are studying two different immune therapy treatments for patients with resectable stage III melanoma. Our goal is to see which treatment may help improve survival without disease progression.

Stage III Malignant MelanomaConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesDermatologyOncology

Metastatic Colorectal Cancer: New Diagnostic Test for Treatment Guidance

We are studying a new test to help doctors determine the best third-line therapy for patients with metastatic colorectal cancer. The goal is to see if this test provides accurate and reliable information for treatment decisions.

Metastatic Colorectal Cancer>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesInternal MedicineOncology

Chronic Rhinosinusitis: Stopping Treatment Study

We are investigating if patients with severe nasal polyps can safely stop treatment after a year without symptoms. We also want to see if one medication works better than the other for achieving this.

Chronic Rhinosinusitis with Nasal Polyps1-2 yearsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesAllergologyOtolaryngology

Reducing Complications After Pancreatoduodenectomy: HOP Bundle Study

We are investigating whether a combination of hydrocortisone, octreotide, and a teres ligament patch can help prevent major complications in patients undergoing high-risk pancreatoduodenectomy. This study also looks at its effect on specific complications like pancreatic fistulas.

Resectable Pancreatic Cancer3-6 monthsMonitoring phase (IV)No PlaceboStandard MedicinesInternal MedicineOncologyOrthopedics and Traumatology

Chronic Limb-Threatening Ischemia: Bone Marrow Cell Therapy

We are comparing a new treatment using your own bone marrow cells with standard care for diabetic patients with severe circulation problems. The goal is to see if this therapy improves tissue oxygen levels and overall health.

Diabetic Foot SyndromeLower Limb Ischemia6-12 monthsEfficacy phase (II)Confirmation phase (III)No PlaceboInvestigational MedicinesCardiologyEndocrinologyInternal MedicineOrthopedics and Traumatology

WSD0922-FU for Advanced Non-Small Cell Lung Cancer

We are studying a new treatment for patients with advanced NSCLC who have a specific mutation and did not respond to prior therapy. The goal is to see if this treatment can help shrink tumors and improve survival.

Non-Small Cell Lung Cancer>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesOncologyPulmonology

GSK4418959 for Solid Tumors: A New Treatment Approach

We are investigating the safety and early effectiveness of the DNA-repair inhibitor GSK4418959 in adults with specific solid tumors. This study looks at the drug alone and with other cancer treatments to see how well it works.

Colorectal Cancer3-6 monthsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology